TickerTalks
Browse all tickers →
TickerTalks›$ALMS
ALALMS

Alumis Inc.

$ALMS·$3.5B·Biotechnology·Healthcare
$27.24-2.7%YTD+186.6%1Y+625.4%
Mentions · last 7 days
2026-07-20: 5 posts2026-07-21: 2 posts2026-07-22: 2 posts2026-07-23: 3 posts2026-07-24: 1 posts2026-07-25: 1 posts2026-07-26: 1 posts15+7%
Price updated just now·X counts updated 20h ago
ALALMS
$ALMSAlumis Inc.
$27.24-2.72%15 posts+7%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $ALMS, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventEvent coming upAI verdict · as of 2026-07-26

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Up 625% in a year on immunology pipeline — Q3 SLE data on envudeucitinib is the make-or-break catalyst.

Alumis is a $3.5B immunology biotech that's absolutely ripped — up 626% over 12 months and 187% YTD — driven by expectations for oral TYK2 inhibitor envudeucitinib in SLE (lupus), with a Q3 2026 data readout being the pivotal catalyst.

  • Pre-commercial financials: essentially no revenue, negative operating margin, PS of 355x. These metrics only make sense in the context of the pipeline story, and the operating burn is manageable given low debt (D/E 0.06).
  • Cantor reiterated Overweight, Stifel reiterated Buy at $44 with a positive PT analysis on the upcoming SLE data. Cormorant and other major biotech funds have added or held large positions per Fool coverage.
  • AyurMaya (Gregory Brown/David Goel) holds 15.1M shares (13D/A #3), a substantial specialist-fund position. Some insider award grants June 30 but no major selling.

X chatter is emphatically bullish — new ATH at $31, chart bulls targeting $111 with invalidation at $29, community grouping ALMS with PTGX as leading oral I&I plays. Next earnings August 12. Bottom line: high-conviction pipeline story with real analyst backing, but the entire thesis is binary on Q3 data — do not confuse the 625% run with a de-risked setup.

Agrees with X sentimentBullish X take is well-supported by analyst coverage and institutional flow, but the binary risk on Q3 SLE data cuts both ways.

What to watch: Q3 2026 envudeucitinib SLE data readout (pivotal), August 12 Q2 print for cash runway, and any interim safety/dosing updates.

On the calendar: 2026-08-12 Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment6 posts analyzed · as of 2026-07-15

Alumis chatter is emphatically bullish. Cantor reiterated Overweight on ALMS. Stifel reiterated Buy at $44 with positive PT analysis on upcoming SLE data (3Q26) - said 'study will likely be successful.' ALMS hit ATH at $31 finally breaking $30 resistance with 3.9B market cap. Community models target 7.5B. Chart bulls target $111 with invalidation at $29 rejection. Community groups ALMS with PTGX as oral I&I companies making great progress. Community broadly long.

Read the AI verdict + X sentiment for $ALMS

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing ESK-001, a selective TYK2 inhibitor, for moderate-to-severe psoriasis and other autoimmune diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ALMS.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $ALMS

Neutral — Clinical-stage biotech developing ESK-001, a selective TYK2 inhibitor, for moderate-to-severe psoriasis and other autoimmune diseases; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+10.9%YTD
+38.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-12.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-71.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-53.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-12.6%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
354.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-54.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
89.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 14, 2026$-0.74$-0.74+0.4%
Q4 2025Mar 19, 2026$-0.95$-0.97+2.1%
Q3 2025Nov 13, 2025$-1.06$-0.92-15.2%
Q2 2025Aug 13, 2025$-1.17$-1.11-5.4%
Next earningsWed, Aug 12·consensus EPS $-0.70

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$1.7M-90.0%50.0%-5652%$-0.74$-87.2M
Q4 FY25$1.9M—100%-5000%$-0.89$-71.9M
Q3 FY25$2.1M—100%-5580%$-1.06$-110.9M
Q2 FY25$2.7M—100%-5272%$0.78$-107.0M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$7.8M$1.5M – $13.9M-$2.86-$3.15 – -$2.599
FY27$26.5M$8.4M – $49.1M-$2.73-$2.99 – -$2.218
FY28$174.3M$174.2M – $174.3M-$1.95-$2.81 – -$1.006
FY29$426.6M$125.2M – $784.2M-$0.81-$1.69 – -$0.075
FY30$875.8M$257.1M – $1.6B$1.28$0.10 – $2.673

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.88%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+14.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+44.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 85.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-0.715-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 6Sanam PangaliChief Legal Officer5.0K sh$140K
+ 10 other (5 awards · 3 others · 2 exempts) in window

See when $ALMS insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentJul 2SC 13D/A
AI summary

AyurMaya Capital Management Company LP (Gregory A. Brown) and affiliated person David E. Goel filed Amendment No. 3 to their Schedule 13D on Alumis Inc. (ALMS), disclosing a combined position of 15,139,707 shares representing 12.3% of outstanding Class A Common Stock as of May 14, 2026. AyurMaya holds only shared (not sole) voting and dispositive power over all shares, consistent with a fund structure. The stated purpose and any activist intent are not detailed in the available excerpt.

8-KShareholder voteJul 28-K — Item 5.07: Shareholder vote
AI summary

Alumis Inc. (ALMS) held its 2026 Annual Meeting of Stockholders on June 30, 2026, with 123,432,072 shares outstanding and eligible to vote as of the May 5, 2026 record date. The filing reports submission of matters to a shareholder vote (Item 5.07); specific vote results are not included in the available excerpt. This is a routine annual governance event with no expected material operational impact.

SC 13D/AActivist amendmentApr 3SC 13D/A
S-3ASRAuto-shelf registrationMar 19S-3ASR
+ 11 other (2 routine 8-Ks · 2 proxys · 2 earnings 8-Ks · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Alumis (NASDAQ:ALMS) Shares Up 5.7% – What’s Next?defenseworld.net·9d agoAlumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soonseekingalpha.com·32d agoThis Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarterfool.com·64d agoAlumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarterfool.com·71d agoAlumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Backfool.com·73d ago

In themes

Explore the broader themes this ticker is being talked about under.

Best Performers

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$AURA$SLS$ABVX$MRNA$ALLO$IBRX$ABCL$IOVA
Voices on X · last 7 days

No standout posts about $ALMS on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport